Quick Answer
Xenon Pharmaceuticals Inc. reported Long Term Debt of $10.89 million for the year ending 2019.
- Xenon Pharmaceuticals Inc. showed a decrease of -27.5% in Long Term Debt from 2018 to 2019.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 1, 2021.
- XBRL data for this metric is available from 2017 to 2019 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $5.48 million | Q2 2018: $11.72 million | Q3 2018: $14.89 million | Q1 2019: $15.14 million | Q2 2019: $13.20 million | Q3 2019: $11.79 million.
- Over the full 3 years of available data (2017 to 2019), Xenon Pharmaceuticals Inc.'s Long Term Debt has grown by 78.4%.
- Historical annual values: Fiscal year 2019: $10.89 million | Fiscal year 2018: $15.01 million | Fiscal year 2017: $6.10 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: